schenkelstegman.com

vascularpharma.com

Vascular Pharmaceuticals - VPI-2690B is a first-in-class mAb for diabetic nephropathy

http://www.vascularpharma.com/science/vpi-2690b

In diabetes, high glucose levels cause an increase in αVß3 ligands (or binding molecules) and stimulate abnormal αVß3 activation. This over activation signals cellular changes that break down filtering capability and decrease kidney function. VPI-2690B prevents these ligands from binding, which normalizes the signaling process and prevents cellular changes. This stops further kidney damage from occurring and may also result in damage reversal. Is currently ongoing and is enrolling new patients.

vascularpharma.com

Vascular Pharmaceuticals - down regulate specific receptor to address diabetic nephropathy

http://www.vascularpharma.com/science

An entirely new approach to address diabetic nephropathy. Vascular Pharmaceuticals is working to address the complications of diabetes by changing the way the disease impacts the body. Diabetic nephropathy. Vascular Pharmaceuticals Completes $9 Million Expansion.

vascularpharma.com

Vascular Pharmaceuticals - developing treatments for diabetic complications, nephropathy

http://www.vascularpharma.com/company

A new treatment option for individuals living with diabetic complications. Vascular Pharmaceuticals, Inc. is a private biopharmaceutical company working to address the complications of diabetes, specifically diabetic nephropathy. There is a serious unmet need for effective treatments for this patient population, which includes both Type 1 and Type 2 diabetics. Founded in 2005, the company is advancing our therapeutic candidate, VPI-2960B,. At more than 40 locations across the United States.

vascularpharma.com

Vascular Pharmaceuticals - Phase 2 clinical trial enrolling diabetic nephropathy patients

http://www.vascularpharma.com/clinical-trials

Currently enrolling patients in a Phase 2 clinical trial. A Phase 2 clinical trial of VPI-2960B. For the treatment of diabetic nephropathy. Is currently enrolling patients with Type 1 and Type 2 diabetes. The 48-week double-blind study is designed to evaluate VPI-2690B compared to placebo in reducing urinary albumin/creatinine ratio (primary endpoint) and improving Estimated Glomerular Filtration Rate (eGFR) levels, both key measures of kidney function.

vascularpharma.com

Vascular Pharmaceuticals - Press releases for Vascular Pharmaceuticals

http://www.vascularpharma.com/news-publications/vascular-pharmaceuticals-initiates-phase-2-clinical-trial

Vascular Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of VPI-2690B for Diabetic Nephropathy. Chapel Hill, NC, November 13, 2014,. VPI-2690B represents an entirely novel approach to the treatment of diabetic nephropathy and pre-clinical evidence demonstrates that VPI-2690B may slow the development and progression of decline in kidney function without any evidence of detrimental side effects," said David Clemmons, M.D., Founder and Chief Scientific Officer of Vascular Pharmaceuticals. The initiat...

vascularpharma.com

Vascular Pharmaceuticals - Vascular Pharmaceuticals, Inc. Completes $9 Million Expansion of Series A Financing

http://www.vascularpharma.com/news-publications/vascular-pharmaceuticals-completes-9-million-expansion

Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing. Funding to support Phase 2 clinical trial of VPI-2690B for treatment of diabetic nephropathy. CHAPEL HILL, NC, March 2, 2015,. Approximately 29.1 million people in the United States have diabetes. There is no cure for diabetic nephropathy. Currently approved treatment options include only antihypertensive drugs that affect the renin-angiotensin-aldosterone system and have the ability to delay, but not stop, the pro...

vascularpharma.com

Vascular Pharmaceuticals - Investors and partner, Janssen, provide funding

http://www.vascularpharma.com/company/investors-and-partners

Vascular Pharmaceuticals is focused on rapidly bringing VPI-2960B. Through clinical development so people living with diabetic nephropathy. In conjunction with the initial Series A round we also entered into an agreement with Janssen Biotech in 2012 granting acquisition rights on pre-negotiated terms after completion of the current Phase 2 trial. Through this deal, Vascular Pharmaceuticals received an initial upfront payment and will secure certain contingent milestone payments in return for rights.

vascularpharma.com

Vascular Pharmaceuticals - Diabetic nephropathy can occur when insulin not controlled

http://www.vascularpharma.com/diabetic-nephropathy

Diabetic nephropathy is the leading cause of chronic kidney disease. Chronic Kidney Disease (CKD) occurs when the kidney does not function properly, becomes damaged, or has another type of abnormality. Diabetic nephropathy affects 20-25% of the diabetic population, many of whom are Type 1 or Type 2 diabetics. As the leading cause of CKD, it strikes up to 30% of the 382 million diabetics worldwide and is responsible for 30-40% percent of all End Stage Renal Disease (ESRD) cases. Who are age 60 or older.

vascularpharma.com

Vascular Pharmaceuticals - Press releases and publications for Vascular Pharmaceuticals

http://www.vascularpharma.com/news-publications

Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing •. Vascular Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of VPI-2690B for Diabetic Nephropathy •. Vascular Pharmaceuticals, Inc. Completes $16 Million Equity Financing, Signs Agreement with Janssen Biotech, Inc. •. Maile LA, Gollahon K, Wai C, Dunbar P, Busby W, Clemmons D. Blocking αVß3 Integrin Ligand Occupancy Inhibits the Progression of Albuminuria in Diabetic Rats. Maile LA, Walker H Busby, Timothy C Nich...